Cargando…

Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects

BACKGROUND: Imrecoxib is a novel and moderately selective cyclooxygenase-2 inhibitor with properties of anti-inflammation and alleviating pain, which is widely applied in osteoarthritis patients. The pharmacokinetic data supporting imrecoxib’s rational use in elderly population are not available. PU...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Ling, Shen, Qi, Hu, Chao, Wang, Ying, Zhu, Xiaohong, Shu, Shiqing, Luo, Zhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653025/ https://www.ncbi.nlm.nih.gov/pubmed/36388081 http://dx.doi.org/10.2147/DDDT.S387508

Ejemplares similares

Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
por: Liu, Yani, et al.
Publicado: (2019)

Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis
por: Sun, Xueshan, et al.
Publicado: (2021)

Imrecoxib attenuates bleomycin-induced pulmonary fibrosis in mice
por: Miao, Yang, et al.
Publicado: (2023)

A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis
por: Zong, He-xiang, et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Pharmacodynamics of TD‐0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects
por: Kanodia, Jitendra, et al.
Publicado: (2020)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
por: Kim, Choon Ok, et al.
Publicado: (2016)

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
por: Jing, Shan, et al.
Publicado: (2023)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects
por: Qian, Hongjie, et al.
Publicado: (2023)

Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects
por: Kuang, Yun, et al.
Publicado: (2020)

Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo
por: Li, Wei, et al.
Publicado: (2011)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
por: Hu, Yingying, et al.
Publicado: (2023)

Imrecoxib Inhibits Paraquat-Induced Pulmonary Fibrosis through the NF-κB/Snail Signaling Pathway
por: Jin, Haihao
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
por: Humeniuk, Rita, et al.
Publicado: (2020)

Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects
por: Tiffany, Courtney, et al.
Publicado: (2022)

The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels
por: Gao, Guan-Min, et al.
Publicado: (2017)

Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults
por: Silverman, M. H., et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects
por: Bellaire, Susan, et al.
Publicado: (2019)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
por: Shen, Zancong, et al.
Publicado: (2017)

Celecoxib: a selective cyclooxygenase-2 inhibitor
por: Gandelman, M
Publicado: (2003)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020)

Sedation Effects Produced by a Ciprofol Initial Infusion or Bolus Dose Followed by Continuous Maintenance Infusion in Healthy Subjects: A Phase 1 Trial
por: Hu, Chao, et al.
Publicado: (2021)

A phase I randomized, double‐blinded, placebo‐controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects
por: Lickliter, Jason, et al.
Publicado: (2023)

Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects
por: Sheng, Lei, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
por: Shen, Zancong, et al.
Publicado: (2015)

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
por: van der Aar, Ellen, et al.
Publicado: (2019)

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
por: Chen, Rui, et al.
Publicado: (2022)

Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial
por: Jiang, Yu, et al.
Publicado: (2021)

Effects of a selective cyclooxygenase-2 inhibitor (celecoxib) on fracture healing in rats
por: Li, Kang-Hua, et al.
Publicado: (2013)

Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
por: Oshima, Hiroyuki, et al.
Publicado: (2015)

Cyclooxygenase-1-selective inhibitor SC-560
por: Long, Sihui, et al.
Publicado: (2009)

Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects
por: Forman, Mark, et al.
Publicado: (2019)

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects
por: Lickliter, Jason D., et al.
Publicado: (2020)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
por: Hall, Jesse, et al.
Publicado: (2018)

Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
por: Namour, Florence, et al.
Publicado: (2016)

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects
por: Qian, Hongjie, et al.
Publicado: (2021)

Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects
por: Li, Yinhua, et al.
Publicado: (2019)

The effect of food on the pharmacokinetics of WXFL10203614, a potential selective JAK1 inhibitor, in healthy Chinese subjects
por: Huang, Kai, et al.
Publicado: (2022)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6u7tnophm91fkev9gsn8faut7k